BioSpace News Archive

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its third quarter ended September 30, 2019 on Thursday, November 7.

Amicus Therapeutics announced additional positive interim results from its CLN6 Batten disease gene therapy program licensed from the Abigail Wexner Research Institute at Nationwide Children’s Hospital.

Butterfly Network, makers of the world’s first single-probe whole body ultrasound system, Butterfly iQ, is now making it easier for hospitals and organizations to scale their point of care ultrasound programs through a new suite of tools making ultrasound workflow mobile, system integrations simple and security even more robust.

CARMA platform offers faster manufacturing speeds, broader therapeutic applications, combination opportunities and repeat dosing potential

First Four “Process A” Patients Demonstrate Long-Term Evidence of Increasing and Durable Engraftment Resembling FA Mosaic Patients

A medication currently used to treat insomnia may also be effective in preventing alcohol intake and relapse in alcohol use disorder, according to researchers at the Florey Institute of Neuroscience and Mental Health.

Reference is made to the stock exchange announcement on 18 October 2019 where Nordic Nanovector ASA announced the successful completion of a private placement raising gross proceeds of NOK 242,525,624 and that the board of directors would consider to carry out a repair offering of up to 2,204,778 new shares

Oblique Therapeutics AB announces that Sreesha P Srinivasa is on the list of invited speakers who will be presenting at the RAS- Targeted Drug Discovery Europe Summit in Vienna in February 2020.

Educational Event to Feature Presentations from MRIdian® Users and ESTRO Past President on the Strategic, Economic, Clinical and Technical Aspects of MRI-Guided Radiation Therapy

The Company is revising its full-year 2019 GAAP earnings per share guidance to a new range of $0.61 to $0.66 and reaffirming full-year adjusted EPS guidance